Agenda Archive

KEYNOTE: How do you increase patient accessibility for your clinical trials to enroll the right patients while ensuring patient safety

Assessing the link between eligibility criteria and the potential for a serious adverse event to make an informed decision about potentially expanding the exclusion criteria of a trial
Discovering alternative solutions to improve patient enrollment into trials
Where are you getting your data for entry criteria?
How have the increased pressures of patient recruitment led to changing and expanding your traditional enrollment methods? What are you doing differently to increase enrollment?
Ensuring your entry criteria are not too conservative but remain safe so that you can reach real world populations
What are the criteria that are major barriers for underrepresented minorities?
How are you using AI to interrogate which criteria to change?

Changing how researchers select potential patients for better success rates
How to improve drug efficacy and patient safety before it’s too late
Back to square one: Differentiating with simpler, patient-centric protocols and optimised study design
Avoiding disappointing results by implementing the right technology tools to advance your trial
Lessons learned to mitigate trial failures

Moderator: Sumeet Ambarkhane, Chief Medical Officer, Pathios Therapeutics

Improving the sense of security to reduce unnecessary suffering and distress for patients
Understanding the different types of patients and their individual response behaviours
Being hyper aware of cultural differences and biases to ensure sensitivity and effective outcomes for all
Sharing best practice on effective strategies with case studies and examples to help reduce patient drop out rate

Integrating the right biomarker to narrow relevant patient groups and optimise and personalise disease management
Engaging with the oncology community and advocacy groups to grow involvement of well-informed patients
Leveraging investigator expertise for pragmatic trial designs and patient identification
Building the evidence, from natural history to endpoint development, to support informed decisions by health authorities

Are global CROs the only viable solution for multinational drug development clinical trials?
Avoiding the misalignment of incentives between service providers and biotechs to prevent sponsor dissatisfaction
Thinking objectively when selecting CRO partnerships by using a data-based approach rather than relying on previous relationships and trials
How to best implement innovative e-clinical software systems to ensure they work within the CRO universe

Predictions for 2026 – Are adaptive trials possible and what will they look like?
Enabling data-driven modifications during the trial to yield better and more useful data and solve time and resource hurdles
Considering the right sample size for study planning: How is this communicated to add transparency to trial design understanding and facilitate robust planning
Enhancing clinical trial speed, safety and effectiveness whilst remaining regulation compliant